Amgen (AMGN) Operating Expenses (2009 - 2026)
Amgen (AMGN) posted quarterly Operating Expenses of $6.0 billion for Q1 2026, down 14.62% year-over-year from $7.0 billion in Q1 2025, and down 16.71% quarter-over-quarter from $7.1 billion in Q4 2025.
Amgen (AMGN) Operating Expenses (2009 - 2026) Analysis & Trends
Amgen's Operating Expenses history runs 18 years deep, the most recent figure standing at $6.0 billion for Q1 2026.
- In Q1 2026, Operating Expenses fell 14.62% year-over-year to $6.0 billion; the TTM figure through Mar 2026 stood at $26.7 billion (changed 0.11% YoY), while the FY2025 annual figure was $27.7 billion, up 5.75% from the prior year.
- Operating Expenses for Q1 2026 stood at $6.0 billion, down from $7.1 billion in the prior quarter.
- The five-year high for Operating Expenses was $7.1 billion in Q4 2025, with the low at $3.7 billion in Q1 2022.
- The 5-year median for Operating Expenses is $6.5 billion (2024), against an average of $5.7 billion.
- The sharpest annual moves came in 2022 and 2024: Operating Expenses fell 22.46% in 2022, then surged 54.3% in 2024.
- Amgen's Operating Expenses stood at $4.6 billion in 2022, then soared by 50.25% to $6.9 billion in 2023, then decreased by 2.17% to $6.8 billion in 2024, then climbed by 5.48% to $7.1 billion in 2025, then declined by 16.71% to $6.0 billion in 2026.
- Business Quant data shows AMGN's Operating Expenses at $6.0 billion in Q1 2026, $7.1 billion in Q4 2025, and $7.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 10.12 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 10.56 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 12.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 6.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 9.70 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 6.54 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 18.20 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 6.68 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -7.60 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -5.98 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.54 Bn |
| Mar 31, 2026 | 5.95 Bn |
| Dec 31, 2025 | 7.15 Bn |
| Sep 30, 2025 | 7.03 Bn |
| Jun 30, 2025 | 6.52 Bn |
| Mar 31, 2025 | 6.97 Bn |
| Dec 31, 2024 | 6.78 Bn |
| Sep 30, 2024 | 6.46 Bn |
| Jun 30, 2024 | 6.48 Bn |
| Mar 31, 2024 | 6.46 Bn |
| Dec 31, 2023 | 6.93 Bn |
| Sep 30, 2023 | 4.88 Bn |
| Jun 30, 2023 | 4.30 Bn |
| Mar 31, 2023 | 4.18 Bn |
| Dec 31, 2022 | 4.61 Bn |
| Sep 30, 2022 | 3.99 Bn |
| Jun 30, 2022 | 4.42 Bn |
| Mar 31, 2022 | 3.74 Bn |
| Dec 31, 2021 | 4.54 Bn |
| Sep 30, 2021 | 4.33 Bn |